Company

RDD Pharma, Ltd.

Tel Aviv biopharmaceutical company developing therapeutics for anorectal diseases, including the Capository drug-delivery system.

About

RDD Pharma, Ltd. develops and commercializes therapeutics for anorectal diseases and gastrointestinal disorders, led by the Capository drug-delivery system for fecal incontinence and pruritus ani, and a compound for radiation proctitis in preclinical development. Founded in 2008 and headquartered in Tel Aviv-Yafo, Israel, it raised USD 9.5 mn in a Series B round on November 16, 2017, led by Pharmascience and joined by Capital Point and OrbiMed Advisors. It is listed at the Series B stage.

2Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in